NYSE$BHVN
Biohaven Ltd old · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Biohaven reported financial results for the first quarter ended March 31, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
Biohaven reported a net loss of $70.5 million, or $1.03 per share, for the first quarter of 2023. The company is advancing its pipeline of therapies for neurological and neuropsychiatric diseases and expects to reach significant pipeline milestones in the coming periods.
- Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China).
- Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy.
- Taldefgrobep alfa granted Fast Track Designation in SMA.
- Driving strong and consistent progress across six robust drug development platforms in 2023.
Headline financials
Revenue & EPS history
Biohaven · Revenue · Quarterly
-$21K
Forward guidance
Biohaven expects to reach significant pipeline milestones in the coming periods.
Tailwinds
- Initiate EEG study with BHV-7000 in the first half of 2023.
- Following Phase 1 study completion, Biohaven expects to initiate pivotal trials in patients with epilepsy and patients with bipolar disorder in the second half of 2023.
- Submit IND with BHV-7010 in epilepsy and mood disorders in the second half of 2023.
- Submit IND with BHV-2100 in chronic pain in the second half of 2023.
- Submit IND with BHV-1300 in the second half of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q1 2023
-0.5%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+7.7%
Avg return
30 days after
50%
7 / 14 earnings
Positive
+12.6%
Q2 2024
Best reaction
-12.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -9.7% | -16.0% | -17.0% | |
| Q3 2024 | -6.5% | +0.5% | +28.3% | |
| Q3 2025 | -5.7% | +0.5% | +28.3% | |
| Q2 2025 | -9.0% | +6.6% | -5.0% | |
| Q1 2025 | +0.0% | -3.7% | -5.2% | |
| Q4 2024 | -2.2% | -7.1% | -36.3% | |
| Q2 2024 | +12.6% | +13.7% | +6.7% | |
| Q1 2024 | -12.5% | -8.7% | -17.5% | |
| Q4 2023 | +4.7% | +24.0% | +15.6% | |
| Q3 2023 | +1.0% | +4.6% | +30.9% | |
| Q2 2023 | +3.1% | +3.4% | -3.3% | |
| Q1 2023 | +5.3% | +2.2% | +72.6% | |
| Q4 2022 | +10.4% | +5.4% | +10.8% | |
| Q3 2022 | +1.2% | +2.2% | -0.9% | |
| Q2 2022 | — | — | — | |
| Q1 2022 | — | — | — | |
| Q4 2021 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro